A randomized, double-blinded, placebo-controlled subcutaneously-administered multi-dose Phase 2b trial of ANB020 in moderate-to-severe baseline adult peanut allergy patients

Trial Profile

A randomized, double-blinded, placebo-controlled subcutaneously-administered multi-dose Phase 2b trial of ANB020 in moderate-to-severe baseline adult peanut allergy patients

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Etokimab (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2018 According to an AnaptysBio media release, the company has decided to deprioritize further the company-sponsored clinical development of Etokimab in peanut allergy patients, as , the company is not intent to use its resources to pursue a Phase 2b clinical trial of etokimab in peanut allergy.
    • 08 May 2018 According to an AnaptysBio media release, the Company anticipates that severity symptoms of all patients in the trial will be adjudicated during baseline and post-treatment oral food challenges by an independent, blinded assessor in accordance with PRACTALL guidelines, and any patients that demonstrate mild severity of symptoms at baseline will be excluded from enrollment in the trial.
    • 02 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top